However, there is currently only one clinical study investigating the combination of RLT with chemotherapy for prostate cancer, UpFrontPSMA (NCT04343885), in which patients with metastatic hormone-naïve prostate cancer receive either a combination of docetaxel (six cycles, every 3 weeks) with [177Lu]Lu-PSMA-617 (two sequential doses, 6 weeks apart), or docetaxel alone. The gene discussed is FOLH1; the disease is prostate carcinoma.